{"symbol":"LLY","fiscalQuarter":"Q3-2025","reportDate":"2025-10-30","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2025","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Up 3.81%","keyNumbers":[{"metric":"EPS","actual":"$7.02","expected":"N/A","surprise":"+16.59%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based on numerical results only."},"guidanceChanges":{"summary":"No guidance data is available.","changes":[]},"whatItMeans":"Eli Lilly reported a strong earnings per share figure that exceeded expectations, contributing to a positive stock reaction of 3.81%. However, without revenue data or management commentary, it's difficult to assess the full context of the company's performance. Investors may view the EPS beat as a positive sign for future profitability.","metaDescription":"Eli Lilly (LLY) Q3 2025 earnings: EPS beat by 16.59%. Stock up 3.81%. Full breakdown."}}